ENGN
enGene Therapeutics Inc.
$1.90
-0.02 (-1.04%)
At close · Jul 10
Market Cap
$127.28M
Shares
66,989,466
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.90
Open$1.92
Day$1.85–1.93
52W$1.40–12.25
Avg vol 30d1.1M
Short int1.1M · 1.7% float · 1.0d
Short vol47%
DataFeb 2022–Jul 2026
Filing10-Q · Jun 15
Up next
FQ3-26 quarter ends
~Jul 31, 2026
Est
filed Jun 15, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−72%
below
Price vs 50-day avg
−22%
below
RSI (14)
45
neutral
MACD trend
Positive
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
−79%
trailing
YTD return
−79%
this year
Relative strength
−88%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
1 of 61 funds reported for Jun 30 · net +150.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.70% of float · ▼ -17.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
61 holders — near 2-yr high, broad support
Squeeze score
38
low risk · 0–100
Fundamentals
EPS growth
+57%
Y/Y
Free cash flow
$-100.7M
Valuation
P/E 0.8
below peers
Balance sheet
$50.2M
net cash
Quant / Vol
risk profile
Volatility
123%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−72%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
45
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
1 of 61 funds reported for Jun 30 · net +150.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.70% of float · ▼ -17.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
61 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 5%
52-wk high $12
vs 200-day avg -72%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENGN
this stock
enGene Therapeutics Inc.
|
$127.28M | -79.0% | — | 0.8 | 1.7% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
62
- % held
- 84.0%
- Reported
- 1 of 61
- Top holder
- FCPM III SERVICES B.V.
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENGN | +6.7% | +18.8% | -79.4% | +9.8% | -79.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +5.4% | +14.7% | -88.5% | +8.7% | -89.7% |